Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dewei She

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Annals of Human Genetics|June 4, 2009
Testing Hardy-Weinberg equilibrium using family data from complex surveysDewei She, Hong Zhang, Zhaohai Li
Biostatistics (Oxford, England)|September 12, 2009
Trend tests for genetic association using population-based cross-sectional complex survey dataDewei She, Yan Li, Hong Zhang, et al.
Drug Metabolism and Pharmacokinetics|April 7, 2018
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteersPaul Baverel, Dewei She, Edward Piper, et al.
Pharmacoepidemiology and Drug Safety|June 19, 2003
Impact of cisapride label changes on codispensing of contraindicated medicationsJeff Jianfei Guo, Suellen Curkendall, Judith K Jones, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2021
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trialMary Rensel, Aram Zabeti, Maureen A Mealy, et al.
British Journal of Clinical Pharmacology|March 25, 2022
Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disordersLi Yan, Bing Wang, Dewei She, et al.
Annals of Epidemiology|July 26, 2005
Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patientsSuellen M Curkendall, Cynthia DeLuise, Judith K Jones, et al.
British Journal of Clinical Pharmacology|July 18, 2015
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosingPaul G Baverel, Meena Jain, Iwona Stelmach, et al.
American Journal of Respiratory and Critical Care Medicine|July 2, 2016
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe AsthmaChristopher E Brightling, Lars H Nordenmark, Meena Jain, et al.
Journal of the American Academy of Dermatology|December 15, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trialEric L Simpson, Jane R Parnes, Dewei She, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Annals of Human Genetics|June 4, 2009
Testing Hardy-Weinberg equilibrium using family data from complex surveysDewei She, Hong Zhang, Zhaohai Li
Biostatistics (Oxford, England)|September 12, 2009
Trend tests for genetic association using population-based cross-sectional complex survey dataDewei She, Yan Li, Hong Zhang, et al.
Drug Metabolism and Pharmacokinetics|April 7, 2018
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteersPaul Baverel, Dewei She, Edward Piper, et al.
Pharmacoepidemiology and Drug Safety|June 19, 2003
Impact of cisapride label changes on codispensing of contraindicated medicationsJeff Jianfei Guo, Suellen Curkendall, Judith K Jones, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2021
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trialMary Rensel, Aram Zabeti, Maureen A Mealy, et al.
British Journal of Clinical Pharmacology|March 25, 2022
Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disordersLi Yan, Bing Wang, Dewei She, et al.
Annals of Epidemiology|July 26, 2005
Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patientsSuellen M Curkendall, Cynthia DeLuise, Judith K Jones, et al.
British Journal of Clinical Pharmacology|July 18, 2015
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosingPaul G Baverel, Meena Jain, Iwona Stelmach, et al.
American Journal of Respiratory and Critical Care Medicine|July 2, 2016
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe AsthmaChristopher E Brightling, Lars H Nordenmark, Meena Jain, et al.
Journal of the American Academy of Dermatology|December 15, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trialEric L Simpson, Jane R Parnes, Dewei She, et al.
Pageof 4